Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy.
NK cells
PD-1
immuno-checkpoint inhibitors (ICI)
non-small cell lung cancer (NSCLC)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Oct 2022
14 Oct 2022
Historique:
received:
14
09
2022
revised:
09
10
2022
accepted:
12
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) immunotherapy has represented a breakthrough in cancer treatment. Clinical use of ICIs has shown an acceptable safety profile and promising antitumor activity. Nevertheless, some patients do not obtain clinical benefits after ICIs therapy. In order to improve and cure an increasing number of patients, the field has moved toward the discovery of new ICIs expressed by cells of innate immunity with an elevated inherent antitumor activity, such as natural killer cells. This review will focus on the recent findings concerning the role of classical and non-classical immune checkpoint molecules and receptors that regulate natural killer cell function, as potential targets, and their future clinical application.
Identifiants
pubmed: 36291830
pii: cancers14205046
doi: 10.3390/cancers14205046
pmc: PMC9599824
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca su Cancro
ID : IG 25023
Organisme : Associazione Italiana per la Ricerca su Cancro
ID : ID.21073
Organisme : Italian Ministry of Health
ID : RF-2018-12366714
Organisme : Italian Ministry of Health
ID : RF-2016-02362288
Références
Pharmaceuticals (Basel). 2022 Mar 09;15(3):
pubmed: 35337133
Eur J Immunol. 2021 Aug;51(8):1934-1942
pubmed: 34145579
Cancer Immunol Immunother. 2013 Dec;62(12):1841-9
pubmed: 24162108
J Hematol Oncol. 2021 Apr 21;14(1):68
pubmed: 33883013
Mol Cells. 2021 Aug 31;44(8):541-548
pubmed: 34373366
J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3
pubmed: 27372564
Int Immunopharmacol. 2015 Dec;29(2):635-641
pubmed: 26428847
N Engl J Med. 2022 Jan 6;386(1):24-34
pubmed: 34986285
Nat Immunol. 2017 Aug;18(8):940-950
pubmed: 28628092
Lancet. 2000 Nov 25;356(9244):1795-9
pubmed: 11117911
Cureus. 2019 Apr 6;11(4):e4401
pubmed: 31245191
Cancer Discov. 2020 Dec;10(12):1854-1871
pubmed: 32826231
Blood. 2012 Apr 19;119(16):3734-43
pubmed: 22383801
Front Immunol. 2020 Feb 21;11:275
pubmed: 32153582
Immunol Rev. 2019 Jan;287(1):202-225
pubmed: 30565241
Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17460-17469
pubmed: 31409707
PLoS One. 2014 Oct 09;9(10):e109976
pubmed: 25299645
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
Nature. 2015 Jan 15;517(7534):386-90
pubmed: 25363763
Oncoimmunology. 2022 Jul 6;11(1):2096359
pubmed: 35813574
Cancer Res. 2011 Aug 15;71(16):5412-22
pubmed: 21708957
Front Immunol. 2018 Nov 29;9:2821
pubmed: 30555485
J Pathol. 2021 Nov;255(3):243-256
pubmed: 34339045
Clin Cancer Res. 2020 Oct 15;26(20):5520-5533
pubmed: 32591463
Sci Transl Med. 2019 Jul 17;11(501):
pubmed: 31316010
J Clin Invest. 2018 Oct 1;128(10):4654-4668
pubmed: 30198904
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Clin Cancer Res. 2021 Jul 1;27(13):3620-3629
pubmed: 33883177
Cancers (Basel). 2020 Aug 26;12(9):
pubmed: 32858904
Cell. 2020 Feb 20;180(4):749-763.e13
pubmed: 32059780
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Nature. 1998 Feb 19;391(6669):795-9
pubmed: 9486650
Immunol Invest. 2015;44(6):578-89
pubmed: 26214042
Nat Immunol. 2017 Jul 19;18(8):870-872
pubmed: 28722713
Immunity. 1999 Nov;11(5):603-13
pubmed: 10591185
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Front Immunol. 2020 Feb 07;11:125
pubmed: 32117275
Int J Cancer. 2020 Oct 1;147(7):1963-1969
pubmed: 32141617
Trends Immunol. 2019 Feb;40(2):142-158
pubmed: 30639050
Front Immunol. 2018 Aug 31;9:1909
pubmed: 30233564
Science. 2016 Apr 22;352(6284):459-63
pubmed: 27102484
J Transl Med. 2019 May 20;17(1):165
pubmed: 31109341
Clin Cancer Res. 2022 Feb 1;28(3):468-478
pubmed: 34667025
Lancet Oncol. 2019 Aug;20(8):1160-1170
pubmed: 31253572
Onco Targets Ther. 2016 Aug 12;9:5023-39
pubmed: 27574444
MAbs. 2022 Jan-Dec;14(1):2018960
pubmed: 35014603
Annu Rev Immunol. 2021 Apr 26;39:417-447
pubmed: 33902312
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199-204
pubmed: 9560253
Cancer Immunol Res. 2022 Mar 1;10(3):291-302
pubmed: 35078821
Nat Immunol. 2009 Jan;10(1):48-57
pubmed: 19011627
Annu Rev Immunol. 1996;14:619-48
pubmed: 8717527
Hepatology. 2019 Jul;70(1):168-183
pubmed: 30411378
Lung Cancer. 2002 Jan;35(1):23-8
pubmed: 11750709
J Thorac Cardiovasc Surg. 2001 Jun;121(6):1058-63
pubmed: 11385371
Leukemia. 2021 Mar;35(3):777-786
pubmed: 32601377
Sci Rep. 2021 Nov 18;11(1):22502
pubmed: 34795387
Crit Rev Immunol. 2018;38(6):479-489
pubmed: 31002602
Cancer Res. 2017 Dec 15;77(24):7059-7071
pubmed: 29042417
Leuk Lymphoma. 2022 Apr;63(4):975-983
pubmed: 34818965
Front Immunol. 2019 Jun 04;10:1242
pubmed: 31214193
Blood. 2018 Apr 19;131(16):1809-1819
pubmed: 29449276
Oncotarget. 2016 Nov 8;7(45):72961-72977
pubmed: 27662664
Lancet Oncol. 2019 Aug;20(8):1083-1097
pubmed: 31221619
J Immunol. 2000 May 15;164(10):5019-22
pubmed: 10799855
Clin Cancer Res. 2020 Oct 15;26(20):5274-5275
pubmed: 32817077
Nat Immunol. 2018 May;19(5):453-463
pubmed: 29632329
Sci Transl Med. 2022 Jul 13;14(653):eabm9043
pubmed: 35857639
Nat Immunol. 2018 Jul;19(7):723-732
pubmed: 29915296
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Front Immunol. 2019 Dec 06;10:2865
pubmed: 31867015
Mol Aspects Med. 2021 Aug;80:100870
pubmed: 32800530
Oncogene. 2017 Nov 2;36(44):6143-6153
pubmed: 28692048
Sci Adv. 2022 Apr 15;8(15):eabj3286
pubmed: 35417234
Cancers (Basel). 2020 Nov 06;12(11):
pubmed: 33172030
J Immunol. 2017 Dec 15;199(12):4091-4102
pubmed: 29127145
Clin Cancer Res. 2016 Nov 1;22(21):5211-5222
pubmed: 27307594
Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2122379119
pubmed: 35696582
Lung Cancer. 2019 Jan;127:153-163
pubmed: 30642544
Oncotarget. 2018 Apr 03;9(25):17675-17688
pubmed: 29707140
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
J Immunol. 2014 Apr 15;192(8):3805-15
pubmed: 24646734
Expert Opin Biol Ther. 2022 Oct;22(10):1259-1273
pubmed: 35994596
JCI Insight. 2019 Dec 5;4(23):
pubmed: 31801909
Front Immunol. 2016 Jun 30;7:262
pubmed: 27446091
Nat Rev Immunol. 2016 Apr 28;16(5):310-20
pubmed: 27121652
Blood. 2010 Sep 30;116(13):2286-94
pubmed: 20460501
Oncotarget. 2016 Nov 8;7(45):73830-73844
pubmed: 27650544
Front Immunol. 2022 Mar 31;13:830396
pubmed: 35464486
Front Oncol. 2022 Jul 19;12:931995
pubmed: 35965506
J Clin Oncol. 2018 Nov 10;36(32):3223-3230
pubmed: 30265610
Immunotherapy. 2017 Mar;9(4):347-360
pubmed: 28303764
Cancer Immunol Res. 2014 May;2(5):410-22
pubmed: 24795354
J Clin Invest. 2018 Apr 2;128(4):1384-1396
pubmed: 29324443
Transl Oncol. 2021 Jan;14(1):100930
pubmed: 33186888
Eur J Immunol. 2020 Aug;50(8):1126-1141
pubmed: 32222966
Mol Cancer. 2020 Aug 6;19(1):120
pubmed: 32762681
Eur J Immunol. 2010 Jun;40(6):1768-77
pubmed: 20391435
Immunol Rev. 2017 Mar;276(1):112-120
pubmed: 28258695
Anticancer Agents Med Chem. 2021;21(4):532-541
pubmed: 32723260
Blood. 2012 Jun 14;119(24):5758-68
pubmed: 22544698
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Annu Rev Immunol. 2006;24:257-86
pubmed: 16551250